Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Voucher Fee Rises 4.6% For Fiscal 2018

Executive Summary

As of Oct. 1, the fee for rare pediatric disease and tropical disease priority review vouchers will be $2.83m; the increase follows a slight decline in FY 2017.

You may also be interested in...

Voucher Bargain: US FDA Lowers Redemption Fee; NDA And BLA Review Costs Decrease

Additional fee will be less than traditional PDUFA application fee in FY 2019, meaning voucher redemptions will cost less than double a typical application review.

NDA User Fees Will Climb Almost 16% On Oct. 1

US FDA completes updates for biosimilars and novel drug fee schedules as PDUFA VI is set to begin.

Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access

US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts